Human helminth therapy to treat inflammatory disorders- where do we stand?

BMC Immunology

Helena Helmby¹ 

[1] Department of Immunology and Infection, Faculty of infectious and Tropical Diseases, London School of Hygiene and Tropical Medicine, Keppel street, London WC1E 7HT, UK

关键词: Autoimmunity;    Regulation;    Inflammation;    Helminths;   

Others  :  1149082
DOI  :  10.1186/s12865-015-0074-3

 received in 2014-10-07, accepted in 2015-02-05,  发布年份 2015

【 摘 要 】

Parasitic helminths have evolved together with the mammalian immune system over many millennia and as such they have become remarkably efficient modulators in order to promote their own survival. Their ability to alter and/or suppress immune responses could be beneficial to the host by helping control excessive inflammatory responses and animal models and pre-clinical trials have all suggested a beneficial effect of helminth infections on inflammatory bowel conditions, MS, asthma and atopy. Thus, helminth therapy has been suggested as a possible treatment method for autoimmune and other inflammatory disorders in humans.

【 授权许可】

   
2015 Helmby; licensee BioMed Central.

【 参考文献 】

• [1]Gerrard JW, Geddes CA, Reggin PL, Gerrard CD, Horne S. Serum IgE levels in white and metis communities in Saskatchewan. Ann Allergy. 1976; 37(2):91-100.
• [2]Strachan DP. Hay fever, hygiene, and household size. BMJ. 1989; 299(6710):1259-60.
• [3]Asher MI, Montefort S, Björksten B, Lai CKW, Strachan DP, Weiland SK et al.. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC phases One and three repeat multicountry cross-sectional surveys. Lancet. 2006; 368(9537):733-43.
• [4]Nicolaou N, Siddique N, Custovic A. Allergic disease in urban and rural populations: increasing prevalence with increasing urbanization. Allergy. 2005; 60(11):1357-60.
• [5]von Mutius E, Vercelli D. Farm living: effects on childhood asthma and allergy. Nat Rev Immunol. 2010; 10(12):861-8.
• [6]Noverr MC, Huffnagle GB. Does the microbiota regulate immune responses outside the gut? Trends Microbiol. 2004; 12(12):562-8.
• [7]Grencis RK, Humphreys NE, Bancroft AJ. Immunity to gastrointestinal nematodes: mechanisms and myths. Immunol Rev. 2014; 260(1):183-205.
• [8]Allen JE, Wynn TA. Evolution of Th2 immunity: a rapid repair response to tissue destructive pathogens. PLoS Pathog. 2011; 7(5):e1002003.
• [9]Wynn TA, Cheever AW, Williams ME, Hieny S, Caspar P, Kühn R et al.. IL-10 regulates liver pathology in acute murine Schistosomiasis mansoni but is not required for immune down-modulation of chronic disease. J Immunol. 1998; 160(9):4473-80.
• [10]Schopf LR, Hoffmann KF, Cheever AW, Urban JF, Wynn TA. IL-10 is critical for host resistance and survival during gastrointestinal helminth infection. J Immunol. 2002; 168(5):2383-92.
• [11]Taylor MD, LeGoff L, Harris A, Malone E, Allen JE, Maizels RM. Removal of regulatory T cell activity reverses hyporesponsiveness and leads to filarial parasite clearance in vivo. J Immunol. 2005; 174(8):4924-33.
• [12]Blankenhaus B, Klemm U, Eschbach ML, Sparwasser T, Huehn J, Kühl AA, et al. Strongyloides ratti infection induces expansion of Foxp3+ regulatory T cells that interfere with immune response and parasite clearance in BALB/c mice. J Immunol. 2011;186(1):4295-4305.
• [13]Bethony J, Brooker S, Albonico M, Geiger SM, Loukas A, Diemert D et al.. Soil-transmitted helminth infections: ascariasis, trichuriasis, and hookworm. Lancet. 2006; 367(9521):1521-32.
• [14]Helmby H. Helminths and our immune system: friend or foe? Parasitol Int. 2009; 58(2):121-7.
• [15]Elliott DE, Weinstock JV. Helminth–host immunological interactions: prevention and control of immune-mediated diseases. Ann N Y Acad Sci. 2012; 1247(1):83-96.
• [16]Summers RW, Elliott DE, Qadir K, Urban JFJ, Thompson R, Weinstock JV. Trichuris suis seems to be safe and possibly effective in the treatment of inflammatory bowel disease. Am J Gastroenterol. 2003; 98(9):2034-41.
• [17]Summers RW, Elliott DE, Urban JFJ, Thompson R, Weinstock JV. Trichuris suis therapy in Crohn’s disease. Gut. 2005; 54(1):87-90.
• [18]Summers RW, Elliott DE, Urban JFJ, Thompson RA, Weinstock JV. Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial. Gastroenterology. 2005; 128(4):825-32.
• [19]Sandborn WJ, Elliott DE, Weinstock J, Summers RW, Landry-Wheeler A, Silver N et al.. Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn’s disease. Aliment Pharmacol Ther. 2013; 38(3):255-63.
• [20]Coronado Biosciences announces top-line results from its TRUST-1 phase 2 clinical trial of TSO for the treatment of Crohn’s disease. [http://ir.coronadobiosciences.com/Cache/1500053219.PDF?Y=&O=PDF&D=&FID=1500053219&T=&IID=4308955]
• [21]Coronado biosciences announces indpendent data monitoring committee recommendation to discontinue falk phase 2 trials of TSO in Chrohn’s disease. [http://ir.coronadobiosciences.com/Cache/1500053915.PDF?Y=&O=PDF&D=&FID=1500053915&T=&IID=4308955]
• [22]Croese J, O’neil J, Masson J, Cooke S, Melrose W, Pritchard D et al.. A proof of concept study establishing Necator americanus in Crohn’s patients and reservoir donors. Gut. 2006; 55(1):136-7.
• [23]McSorley HJ, Gaze S, Daveson J, Jones D, Anderson RP, Clouston A et al.. Suppression of inflammatory immune responses in celiac disease by experimental hookworm infection. PLoS One. 2011; 6(9):e24092.
• [24]Daveson AJ, Jones DM, Gaze S, McSorley H, Clouston A, Pascoe A et al.. Effect of hookworm infection on wheat challenge in celiac disease ‚ a randomised double-blinded placebo controlled trial. PLoS One. 2011; 6(3):e17366.
• [25]Leonardi-Bee J, Pritchard D, Britton J. Asthma and current intestinal parasite infection. Am J Respir Crit Care Med. 2006; 174(5):514-23.
• [26]Cooper PJ. Interactions between helminth parasites and allergy. Curr Opin Allergy Clin Immunol. 2009; 9(1):29-37.
• [27]Cooper PJ, Chico ME, Vaca MG, Moncayo AL, Bland JM, Mafla E et al.. Effect of albendazole treatments on the prevalence of atopy in children living in communities endemic for geohelminth parasites: a cluster-randomised trial. Lancet. 2006; 367(9522):1598-603.
• [28]van Den Biggelaar AH, Rodrigues LC, van Ree R, van der Zee JS, Hoeksma-Kruize YC, Souverijn JH et al.. Long-term treatment of intestinal helminths increases mite skin-test reactivity in Gabonese schoolchildren. J Infect Dis. 2004; 189(5):892-900.
• [29]Flohr C, Tuyen LN, Quinnell RJ, Lewis S, Minh TT, Campbell J et al.. Reduced helminth burden increases allergen skin sensitization but not clinical allergy: a randomized, double-blind, placebo-controlled trial in Vietnam. Clin Exp Allergy. 2010; 40(1):131-42.
• [30]Sereda MJ, Hartmann S, Lucius R. Helminths and allergy: the example of tropomyosin. Trends Parasitol. 2008; 24(6):272-8.
• [31]Fitzsimmons CM, Dunne DW. Survival of the fittest: allergology or parasitology? Trends Parasitol. 2009; 25(10):447-51.
• [32]Santiago HC, Bennuru S, Ribeiro JMC, Nutman TB. Structural differences between human proteins and aero- and microbial allergens define allergenicity. PLoS One. 2012; 7(7):e40552.
• [33]Bager P, Arnved J, Rønborg S, Wohlfahrt J, Poulsen LK, Westergaard T et al.. Trichuris suis ova therapy for allergic rhinitis: a randomized, double-blind, placebo-controlled clinical trial. J Allergy Clin Immunol. 2010; 125(1):123-30.
• [34]Feary J, Venn A, Brown A, Hooi D, Falcone FH, Mortimer K et al.. Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study. Clin Exp Allergy. 2009; 39(7):1060-8.
• [35]Feary JR, Venn AJ, Mortimer K, Brown AP, Hooi D, Falcone FH et al.. Experimental hookworm infection: a randomized placebo-controlled trial in asthma. Clin Exp Allergy. 2010; 40(2):299-306.
• [36]La Flamme AC, Ruddenklau K, Backstrom BT. Schistosomiasis decreases central nervous system inflammation and alters the progression of experimental autoimmune encephalomyelitis. Infect Immun. 2003; 71(9):4996-5004.
• [37]Walsh KP, Brady MT, Finlay CM, Boon L, Mills KHG. Infection with a helminth parasite attenuates autoimmunity through TGF-b-mediated suppression of Th17 and Th1 responses. J Immunol. 2009; 183(3):1577-86.
• [38]Correale J, Farez M. Association between parasite infection and immune responses in multiple sclerosis. Ann Neurol. 2007; 61(2):97-108.
• [39]Correale J, Farez MF. The impact of parasite infections on the course of multiple sclerosis. J Neuroimmunol. 2011; 233(1–2):6-11.
• [40]Fleming JO, Isaak A, Lee JE, Luzzio CC, Carrithers MD, Cook TD et al.. Probiotic helminth administration in relapsing-remitting multiple sclerosis: a phase 1 study. Mult Scler. 2011; 17(6):743-54.
• [41]Harnett W. Secretory products of helminth parasites as immunomodulators. Mol Biochem Parasitol. 2014; 195(2):130-6.
• [42]Zaccone P, Cooke A. Vaccine against autoimmune disease: can helminths or their products provide a therapy? Curr Opin Immunol. 2013; 25(3):418-23.
• [43]Navarro S, Ferreira I, Loukas A. The hookworm pharmacopoeia for inflammatory diseases. Int J Parasitol. 2013; 43(3):225-31.
• [44]Round JL, Mazmanian SK. The gut microbiota shapes intestinal immune responses during health and disease. Nat Rev Immunol. 2009; 9(5):313-23.
• [45]Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “Western-Lifestyle” inflammatory diseases. Immunity. 2014; 40(6):833-42.